Last reviewed · How we verify
PF-06863135 + lenalidomide — Competitive Intelligence Brief
marketed
small molecule + immunomodulatory drug
unknown
Oncology
Live · refreshed every 30 min
Target snapshot
PF-06863135 + lenalidomide (pf-06863135-lenalidomide) — Pfizer.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| PF-06863135 + lenalidomide TARGET | pf-06863135-lenalidomide | Pfizer | marketed | small molecule + immunomodulatory drug | unknown | |
| SINECATECHINS | SINECATECHINS | marketed | Polyphenols | Unknown | 2006-01-01 | |
| PODOFILOX | PODOFILOX | marketed | Topical antiviral | Unknown | 1990-01-01 | |
| POLIDEXIDE SULFATE | POLIDEXIDE SULFATE | marketed | Unknown | Unknown | 1974-01-01 | |
| SUTILAINS | SUTILAINS | marketed | Unknown | Unknown | 1969-01-01 | |
| Gbt021601 | gbt021601 | Pfizer | marketed | unknown | unknown | |
| Pf-08049820 Ir | pf-08049820-ir | Pfizer | marketed | Unknown | Unknown |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — SINECATECHINS · 7858662 · Formulation · US
Sponsor landscape (small molecule + immunomodulatory drug class)
- Pfizer · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- PF-06863135 + lenalidomide CI watch — RSS
- PF-06863135 + lenalidomide CI watch — Atom
- PF-06863135 + lenalidomide CI watch — JSON
- PF-06863135 + lenalidomide alone — RSS
- Whole small molecule + immunomodulatory drug class — RSS
Cite this brief
Drug Landscape (2026). PF-06863135 + lenalidomide — Competitive Intelligence Brief. https://druglandscape.com/ci/pf-06863135-lenalidomide. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing